It was surprising that the benefit of DFS for ICI was not detected in the PD-L1 > 50% group which is likely due to the relative benefit of ICI treatment increasing with increasing PD-L1 expression in the setting of locally advanced or metastatic NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.